论文部分内容阅读
由白细胞介素2(IL-2)和白细胞介素6(IL-6)介导的各种免疫反应已成为某些恶性肿瘤诊断、预后和疗效的监测指标[1～3]。食管癌患者存在一系列免疫调节紊乱[4],但对IL-2和
Various immune responses mediated by interleukin 2 (IL-2) and interleukin-6 (IL-6) have become the indicators for the diagnosis, prognosis and efficacy of certain malignancies [1-3]. Esophageal cancer patients have a series of immune disorders [4], but for IL-2 and